252 related articles for article (PubMed ID: 34440844)
1. Unraveling the IGF System Interactome in Sarcomas Exploits Novel Therapeutic Options.
Mancarella C; Morrione A; Scotlandi K
Cells; 2021 Aug; 10(8):. PubMed ID: 34440844
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract][Full Text] [Related]
3. Development of IGF-IR Inhibitors in Pediatric Sarcomas.
Kolb EA; Gorlick R
Curr Oncol Rep; 2009 Jul; 11(4):307-13. PubMed ID: 19508836
[TBL] [Abstract][Full Text] [Related]
4. Targeting insulin-like growth factor 1 receptor in sarcomas.
Scotlandi K; Picci P
Curr Opin Oncol; 2008 Jul; 20(4):419-27. PubMed ID: 18525338
[TBL] [Abstract][Full Text] [Related]
5. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
You L; Liu C; Tang H; Liao Y; Fu S
Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
[TBL] [Abstract][Full Text] [Related]
6. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
Schwartz GK; Tap WD; Qin LX; Livingston MB; Undevia SD; Chmielowski B; Agulnik M; Schuetze SM; Reed DR; Okuno SH; Ludwig JA; Keedy V; Rietschel P; Kraft AS; Adkins D; Van Tine BA; Brockstein B; Yim V; Bitas C; Abdullah A; Antonescu CR; Condy M; Dickson MA; Vasudeva SD; Ho AL; Doyle LA; Chen HX; Maki RG
Lancet Oncol; 2013 Apr; 14(4):371-82. PubMed ID: 23477833
[TBL] [Abstract][Full Text] [Related]
7. The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer.
Heidegger I; Massoner P; Sampson N; Klocker H
Cancer Lett; 2015 Oct; 367(2):113-21. PubMed ID: 26231734
[TBL] [Abstract][Full Text] [Related]
8. The insulin-like growth factor system and sarcomas.
Rikhof B; de Jong S; Suurmeijer AJ; Meijer C; van der Graaf WT
J Pathol; 2009 Mar; 217(4):469-82. PubMed ID: 19148905
[TBL] [Abstract][Full Text] [Related]
9. Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma.
Garofalo C; Mancarella C; Grilli A; Manara MC; Astolfi A; Marino MT; Conte A; Sigismund S; Carè A; Belfiore A; Picci P; Scotlandi K
Mol Endocrinol; 2012 Sep; 26(9):1603-16. PubMed ID: 22798295
[TBL] [Abstract][Full Text] [Related]
10. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
Kurmasheva RT; Dudkin L; Billups C; Debelenko LV; Morton CL; Houghton PJ
Cancer Res; 2009 Oct; 69(19):7662-71. PubMed ID: 19789339
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling.
Garofalo C; Manara MC; Nicoletti G; Marino MT; Lollini PL; Astolfi A; Pandini G; López-Guerrero JA; Schaefer KL; Belfiore A; Picci P; Scotlandi K
Oncogene; 2011 Jun; 30(24):2730-40. PubMed ID: 21278796
[TBL] [Abstract][Full Text] [Related]
12. Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy.
Bid HK; London CA; Gao J; Zhong H; Hollingsworth RE; Fernandez S; Mo X; Houghton PJ
Clin Cancer Res; 2013 Jun; 19(11):2984-94. PubMed ID: 23549869
[TBL] [Abstract][Full Text] [Related]
13. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
14. IGF-1 receptor inhibitors in clinical trials--early lessons.
Weroha SJ; Haluska P
J Mammary Gland Biol Neoplasia; 2008 Dec; 13(4):471-83. PubMed ID: 19023648
[TBL] [Abstract][Full Text] [Related]
15. Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway.
van Maldegem AM; Bovée JV; Peterse EF; Hogendoorn PC; Gelderblom H
Eur J Cancer; 2016 Jan; 53():171-80. PubMed ID: 26765686
[TBL] [Abstract][Full Text] [Related]
16. Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas.
Potratz JC; Saunders DN; Wai DH; Ng TL; McKinney SE; Carboni JM; Gottardis MM; Triche TJ; Jürgens H; Pollak MN; Aparicio SA; Sorensen PH
Cancer Res; 2010 Nov; 70(21):8770-81. PubMed ID: 20959493
[TBL] [Abstract][Full Text] [Related]
17. β-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma.
Zheng H; Shen H; Oprea I; Worrall C; Stefanescu R; Girnita A; Girnita L
Proc Natl Acad Sci U S A; 2012 Dec; 109(50):20620-5. PubMed ID: 23188799
[TBL] [Abstract][Full Text] [Related]
18. IGF system in sarcomas: a crucial pathway with many unknowns to exploit for therapy.
Mancarella C; Scotlandi K
J Mol Endocrinol; 2018 Jul; 61(1):T45-T60. PubMed ID: 29273680
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy.
Hua H; Kong Q; Yin J; Zhang J; Jiang Y
J Hematol Oncol; 2020 Jun; 13(1):64. PubMed ID: 32493414
[TBL] [Abstract][Full Text] [Related]
20. Targeting IGF-1R in the treatment of sarcomas: past, present and future.
Kim SY; Wan X; Helman LJ
Bull Cancer; 2009; 96(7):E52-60. PubMed ID: 19617179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]